BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36566258)

  • 21. Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence.
    Grange R; Rousset P; Williet N; Guesnon M; Milot L; Passot G; Phelip JM; Le Roy B; Glehen O; Kepenekian V
    Ann Surg Oncol; 2024 Apr; 31(4):2378-2390. PubMed ID: 38170409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcomes of elderly patients with peritoneal metastases of colorectal origin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Weksler Y; Hoffman A; Green E; Kyzer M; Nevo N; Gerstenhaber F; Greenberg R; Klausner JM; Gutman M; Lahat G; Berger Y; Geva R; Nizri E
    Surg Oncol; 2022 Sep; 44():101848. PubMed ID: 36126349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases.
    van der Werf LR; Wassenaar E; de Niet A; Lalezari F; Braam HJ; van Ramshorst B; Nederend J; de Hingh IHJT; Kok NFM; Aalbers AGJ
    Eur J Surg Oncol; 2019 Mar; 45(3):376-382. PubMed ID: 30414704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns and Timing of Recurrence following CRS and HIPEC in Colorectal Cancer Peritoneal Metastasis.
    Hassan S; Malcomson L; Soh YJ; Wilson MS; Clouston H; O'Dwyer ST; Kochhar R; Aziz O
    Eur J Surg Oncol; 2023 Jan; 49(1):202-208. PubMed ID: 35987797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic Chemotherapy for High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread After Unsuccessful CRS/HIPEC.
    Baron E; Sardi A; King MC; Nikiforchin A; Lopez-Ramirez F; Nieroda C; Gushchin V; Ledakis P
    Ann Surg Oncol; 2022 Oct; 29(11):6581-6589. PubMed ID: 35641710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
    Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
    [No Abstract]   [Full Text] [Related]  

  • 29. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
    Bhullar D; O'Dwyer S; Wilson M; Saunders MP; Kochhar R; Barriuso J; Aziz O
    Ann Surg Oncol; 2023 Feb; 30(2):792-801. PubMed ID: 36400886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases.
    Ito K; Takemura N; Inagaki F; Mihara F; Kurokawa T; Gohda Y; Kiyomatsu T; Yano H; Kokudo N
    World J Surg Oncol; 2019 Jun; 17(1):99. PubMed ID: 31196097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era.
    Kelly ME; Murphy E; Keyes AM; Khan MF; Bolger JC; Grundy J; Conneely J; MacHale J; McCaffrey J; Cahill R; Moran B; Shields C; Mulsow J
    Ir J Med Sci; 2021 Nov; 190(4):1373-1377. PubMed ID: 33420573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
    Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
    World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
    Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
    World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
    Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
    BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
    Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
    BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer.
    Mertens LS; Behrendt MA; Mehta AM; Stokkel L; de Jong J; Boot H; Horenblas S; van der Heijden MS; Moonen LM; Aalbers AGJ; Meinhardt W; van Rhijn BWG
    Eur J Surg Oncol; 2019 Sep; 45(9):1740-1744. PubMed ID: 31003721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Mercier F; Passot G; Bonnot PE; Cashin P; Ceelen W; Decullier E; Villeneuve L; Walter T; Levine EA; Glehen O; ;
    World J Surg; 2022 Jun; 46(6):1336-1343. PubMed ID: 35286418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis.
    Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O
    Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases.
    Wach MM; Nunns G; Hamed A; Derby J; Jelinek M; Tatsuoka C; Holtzman MP; Zureikat AH; Bartlett DL; Ahrendt SA; Pingpank JF; Choudry MHA; Ongchin M
    Ann Surg Oncol; 2024 Apr; 31(4):2391-2400. PubMed ID: 38270826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.